Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Consolidated Net Income fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.49% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Consolidated Net Income stood at -$3.4 million for Q3 2025, which was up 82.30% from -$19.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Consolidated Net Income's 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$28.0 million in Q4 2021.
  • Its 3-year average for Consolidated Net Income is -$6.3 million, with a median of -$5.2 million in 2023.
  • Over the last 5 years, Lineage Cell Therapeutics' Consolidated Net Income had its largest YoY gain of 82.82% in 2021, and its largest YoY loss of 2,946.44% in 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' Consolidated Net Income (Quarterly) stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then climbed by 25.90% to -$4.7 million in 2023, then spiked by 31.06% to -$3.2 million in 2024, then fell by 13.96% to -$3.4 million in 2025.
  • Its last three reported values are -$3.4 million in Q3 2025, -$19.3 million for Q2 2025, and -$6.0 million during Q1 2025.